LDS/Medical Tests/Cytochrome P450 1B1 (CYP1B1) Genotyping

Cytochrome P450 1B1 (CYP1B1) Genotyping

CYP1B1 belongs to the cytochrome P450 superfamily of enzymes. The CYP1B1 enzyme is expressed in a variety of tissues including liver, eye, breast, ovary, endometrium and prostate. Although CYP1B1 is expressed in normal tissues, it is expressed at much higher levels in cancer tissues. CYP1B1 enzyme is mostly known for activation of certain procarcinogens (polycyclic aromatic hydrocarbons, aromatic and heterocyclic amines, aflatoxin B1), and hormones such as estrogen. Since it is responsible for activation of some procarcinogens and estrogen metabolism, mutations in CYP1B1 are often associated with many cancers. In particular, high levels of expression are observed in hormone (estrogen)-mediated cancers including breast, ovarian and prostate cancers. Thus, CYP1B1 induction is an important factor in determining risk associated with hormone-mediated cancers.

A recent study has shown that gene variation of this enzyme is closely associated with primary congenital glaucoma (PCG). PCG is an ocular disease characterized by high intraocular pressure (IOP), globe enlargement, edema, corneal opacification, thinning of anterior sclera, iris atrophy, anomalous deep anterior chamber, photophobia, blepharospasm, and excessive tearing. It affects one in every 10,000 infants between the ages of birth and three years. PCG accounts for 4% of all blindness in children.

A study of PCG has identified three loci. However, only mutations in CYP1B1 are found responsible for an autosomal recessive form of PCG. Mutations in CYP1B1 can be detected in 20-100% of familial cases and 10-15% of isolated PCG cases. CYP1B1 mutation may also cause other abnormalities including Peters Anomaly, Rieger anomaly, and malformations in the anterior chamber of the eye. Finding the mutation in CYP1B1 can help provide on-time treatment and proper treatment of PCG. Furthermore, due to its function in hormone metabolism, gene variation can alter tissue response to hormones and alter clinical response to chemotherapy.

  • To confirm a clinical diagnosis of primary congenital glaucoma.
  • Carrier screening for individuals with primary congenital glaucoma family history
  • Diagnosis of hormone-influenced cancers: breast, ovarian and prostate cancer
  • Monitoring and management of cancer hormone therapy 
Two copies of disease causing variants will cause primary congenital glaucoma. Bidirectional Sanger sequencing or Next Generation Sequencing of the entire CYP1B1 coding region, intron-exon boundaries and 5 prime untranslated region should identify potential mutations in CYP1B1 gene.

CYP1B1 \*1/\*1 (Normal metabolizer)

Allele Specific Primer Extension (ARMS) by Real-time Polymerase chain reaction (PCR), Next generation sequencing (NGS), Conventional Sequencing.

Whole blood collected in lavender top (EDTA) tube.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
A complete ophthalmic exam that includes IOP measurement, gonioscopy, inspection of the optic nerve and refraction will be needed to diagnose glaucoma.
7-14 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login